Internship

Intern PhD Student

Materials Characterization/Process Analytical Technologies

Posted on 10/22/2024

Bristol-Myers Squibb

Bristol-Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Biotechnology
Healthcare

Franklin Township, NJ, USA

Interns residing more than 50 miles away from New Brunswick, NJ are eligible for a travel or housing stipend.

Category
Lab & Research
Life Sciences
Required Skills
Data Analysis
Requirements
  • Candidates must be currently enrolled in an accredited university program seeking a Ph.D. in Analytical Chemistry, Physical Chemistry, Materials Science, Pharmaceutical Sciences, Physics, or a related field, with a focus on Materials Characterization or PAT. Candidate must still be enrolled during Summer 2025.
  • Must include GPA on resume; program requires GPA of 3.0 or greater.
  • Expertise related to powders, crystallography, powder flow, particle size analysis, and/or with tools such as spectroscopy, chemometrics, or related techniques for process optimization and monitoring.
  • Additional familiarity with chemometrics is a plus.
  • Excellent critical thinking skills and the ability to work independently and as part of a team.
  • Effective communication and people skills.
  • Proficiency in data analysis software and tools.
Responsibilities
  • Develop methods for product characterization.
  • Develop and implement PAT methods to monitor and control pharmaceutical processes.
  • Design and execute experiments to evaluate PAT tools and develop and validate methods.
  • Collaborate with multi-disciplinary teams, including formulation scientists, analytical chemists, process engineers, and process modelers, to enable drug product formulation development and manufacturing processes.
  • Troubleshoot and resolve issues related to characterization and PAT methodologies.

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

Company Stage

IPO

Total Funding

$33.7B

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • BMS's collaboration with Prime Medicine enhances its cell and gene-therapy pipeline.
  • The rise of digital health technologies boosts BMS's R&D efficiency.
  • BMS's focus on biosimilars opens new market opportunities globally.

What critics are saying

  • BMS faces a $6.4 billion lawsuit over Celgene drug approval delays.
  • The 340B Drug Pricing Program lawsuit could lead to regulatory challenges.
  • High financial stakes in the Prime Medicine agreement pose development risks.

What makes Bristol-Myers Squibb unique

  • BMS focuses on oncology, immunology, and cardiovascular diseases for innovative treatments.
  • The company invests heavily in R&D to develop new drugs and therapies.
  • BMS offers both innovative and generic medicines, increasing healthcare accessibility.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE